Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR) was considering the sale of as much as 3 billion reais ($1.35 billion) of so-called infrastructure notes this quarter, as well as offering euro- and British pound-denominated global bonds before year-end, a source said earlier this year. Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR) shares after opening at $13.67 moved to $14.36 on last trade day and at the end of the day closed at $14.22. Company price to sales ratio in past twelve months was calculated as 0.67 and price to cash ratio as 3.63. Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR) showed a positive weekly performance of 11.79%.
Questcor Pharmaceuticals Inc (NASDAQ:QCOR) Director Stephen C. Farrell unloaded 10,000 shares of the company’s stock on the open market in a transaction dated Monday, April 7th. The stock was sold at an average price of $81.43, for a total value of $814,300.00. Questcor Pharmaceuticals Inc (NASDAQ:QCOR) shares advanced 18.73% in last trading session and ended the day on $80.58. QCOR return on equity ratio is recorded as 94.20% and its return on assets is 50.60%.Questcor Pharmaceuticals Inc (NASDAQ:QCOR) yearly performance is 174.46%.
Idenix Pharmaceuticals, Inc. (NASDQ: IDIX) announced continued progress of the Company’s program to develop nucleotide prodrug inhibitors for the treatment of hepatitis C virus (HCV) infection. Idenix is reporting potent antiviral activity of mean maximum 4.2-4.3 log10 IU/mL reductions for patients infected with HCV genotype 1, 2 or 3 receiving 300 mg once daily of IDX21437 in the seven-day proof-of-concept portion of a phase I/II clinical trial. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) shares moved up 12.38% in last trading session and was closed at $5.81, while trading in range of $ 5.12 – 5.96. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) year to date (YTD) performance is -2.84%.
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) announced that data from its lead, first-in-class program AG-221 will be presented today at a Clinical Trials Symposium titled “Novel Immune and Targeted Therapies for Hematological Malignancies and Solid Tumors” at the American Association for Cancer Research (AACR) Annual Meeting 2014. These preliminary data demonstrate the clinical activity, tolerability and unique mechanism of action of AG-221 in patients with advanced hematologic malignancies with an isocitrate dehydrogenase-2 (IDH2) mutation. Agios Pharmaceuticals Inc (NASDAQ:AGIO) weekly performance is 15.84%. On last trading day company shares ended up $45.35. Agios Pharmaceuticals Inc (NASDAQ:AGIO) distance from 50-day simple moving average (SMA50) is 30.59%. Analysts mean target price for the company is $49.00.
Leave a Reply